Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liposome-encapsulated Daunorubicin-Cytarabine · 1 trial · 4 indications
Defined by the International Working Group Criteria. Will be summarized using frequencies and relative frequencies.
| Arm | Type | Description |
|---|---|---|
| Treatment (CPX-351) | EXPERIMENTAL | INDUCTION: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity. RE-INDUCTION: Patients who do not achieve remission receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Beginning 5-8 weeks after the start of the last induction, patients who achieve CR receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 45 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Liposome-encapsulated Daunorubicin-Cytarabine | DRUG | Given IV |
Inclusion Criteria: * Newly diagnosed: * Therapy-related acute myeloid leukemia (AML) * AML with antecedent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) * AML with MDS-related changes (as per World Health Organization \[WHO\]) * Have an Eastern Cooperative Oncolog...
Liposome-encapsulated Daunorubicin-Cytarabine is being studied for the treatment of acute myeloid leukemia arising from previous myelodysplastic syndrome, as well as acute myeloid leukemia with myelodysplasia-related changes, secondary acute myeloid leukemia, and therapy-related acute myeloid leukemia. It is an investigational small molecule oncology therapy currently in Phase 2 clinical development.
Liposome-encapsulated Daunorubicin-Cytarabine is being developed by Jazz Pharmaceuticals plc, a biopharmaceutical company traded on the stock exchange under the ticker JAZZ. The company is conducting clinical trials to evaluate this investigational therapy for certain types of acute myeloid leukemia.
Liposome-encapsulated Daunorubicin-Cytarabine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants, with a planned enrollment of 21 patients.
Liposome-encapsulated Daunorubicin-Cytarabine is being evaluated in clinical trial NCT04269213, titled 'CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old.' This Phase 2 study is active but not recruiting, enrolls adults aged 18 years and older, and is being conducted in the United States.
Yes, Liposome-encapsulated Daunorubicin-Cytarabine is also known as CPX-351. The clinical trial NCT04269213 uses the name CPX-351 in its title, confirming that these names refer to the same investigational drug being developed by Jazz Pharmaceuticals for certain acute myeloid leukemia indications.